A large Swedish study of 100,000 women found that using AI to assist radiologists reading mammograms reduced the rate of aggressive "interval" breast cancers by 12%. CBC News reports: For the study -- published in Thursday's issue of the medical journal The Lancet -- more than 100,000 women had mammography screenings. Half were supported by AI and the rest had their mammograms reviewed by two different radiologists, a standard practice in much of Europe known as double reading. It is not typically used in Canada, where usually one radiologist checks mammograms. The study looked at the rates of interval cancer, the term doctors use for invasive tumors that appear between routine mammograms. They can be harder to detect and studies have shown that they are more likely to be aggressive with a poorer prognosis. The rate of interval cancers decreased by 12 percent in the groups where the AI screening was implemented, the study showed. [...] Throughout the two-year study, the mammograms that were supported by AI were triaged into two different groups. Those that were determined to be low risk needed only one radiologist to examine them, while those that were considered high risk required two. The researchers reported that numerically, the AI-supported screening resulted in 11 fewer interval cancers than standard screening (82 versus 93, or 12 per cent). "This is really a way to improve an overall screening test," [said lead author, Dr. Kristina Lang]. She acknowledged that while the study found a decrease in interval cancer, longer-term studies are needed to find out how AI-supported screening might impact mortality rates. The screenings for the study all took place at one centre in Sweden, which the researchers acknowledged is a limitation. Another is that the race and ethnicity of the participants were not recorded. The next step, Lang said, will be for Swedish researchers to determine cost-effectiveness.

Read more of this story at Slashdot.

For decades, researchers have noted that cancer and Alzheimer's disease are rarely found in the same person, fuelling speculation that one condition might offer some degree of protection from the other. Nature: Now, a study in mice provides a possible molecular solution to the medical mystery: a protein produced by cancer cells seems to infiltrate the brain, where it helps to break apart clumps of misfolded proteins that are often associated with Alzheimer's disease. The study, which was 15 years in the making, was published on 22 January in Cell and could help researchers to design drugs to treat Alzheimer's disease. "They have a piece of the puzzle," says Donald Weaver, a neurologist and chemist at the Krembil Research Institute at the University of Toronto in Canada, who was not involved in the study. "It's not the full picture by any stretch of the imagination. But it's an interesting piece." [...] A 2020 meta-analysis of data from more than 9.6 million people found that cancer diagnosis was associated with an 11% decreased incidence of Alzheimer's disease. It has been a difficult relationship to unpick: researchers must control for a variety of external factors. For example, people might die of cancer before they are old enough to develop symptoms of Alzheimer's disease, and some cancer treatments can cause cognitive difficulties, which could obscure an Alzheimer's diagnosis.

Read more of this story at Slashdot.